The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy

被引:0
作者
Jerry Meece
机构
[1] Plaza Pharmacy and Wellness Center,Director of Clinical Services
来源
Advances in Therapy | 2017年 / 34卷
关键词
Diabetes; Glucagon-like peptide-1 receptor agonists; Glycemic control; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence and associated clinical burden of type 2 diabetes (T2D) is increasing in the USA and other countries. As a consequence, the role of the pharmacist in managing T2D is expanding, and it is becoming increasingly important for pharmacists to have a complete understanding of the disease course and treatment options. Pharmacists have a key role in the use of injectable therapies, including incretin-based treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This article discusses the role of the pharmacist in the management of patients with T2D, particularly with respect to the use of GLP-1RAs to achieve glycemic control. GLP-1RAs are a class of injectable agents used as an adjunct to diet and exercise to improve glycemic control in adults with T2D. GLP-1RAs have been shown to lower glucose levels, slow gastric emptying, enhance satiety, and reduce body weight without increasing the risk of hypoglycemia. GLP-1RAs currently approved in the USA include exenatide twice daily, liraglutide once daily, and albiglutide, dulaglutide, and exenatide once weekly. Pharmacists can work with physicians to help identify patients for whom GLP-1RA therapy is appropriate. In addition, pharmacists can educate patients regarding medication storage, preparation, and injection techniques, glycated hemoglobin (HbA1c) targets, pre- and post-meal blood glucose goals, adverse events and management strategies, and the long-term benefits of reducing HbA1c. As members of the diabetes care team, pharmacists play an important role in improving patient outcomes.
引用
收藏
页码:638 / 657
页数:19
相关论文
共 246 条
[11]  
Buse JB(1964)Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 24 1076-52
[12]  
Ali MK(1986)Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 46-446
[13]  
Bullard KM(2013)The future of diabetes education: expanded opportunities and roles for diabetes educators Diabetes Educ 39 436-697
[14]  
Gregg EW(2015)Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010) Int J Clin Pharm 37 687-830
[15]  
Wong ND(2016)New transfer of care initiative of electronic referral from hospital to community pharmacy in England: a formative service evaluation BMJ Open 6 e012532-421
[16]  
Patao C(2002)Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 824-460
[17]  
Wong K(2013)Glucagon-like peptide-1 analogues: an overview Indian J Endocrinol Metab. 17 413-27
[18]  
Malik S(2015)The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis PLoS One 10 e0126769-1460
[19]  
Franklin SS(2015)Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: a network meta-analysis Diabetes Res Clin Pract 109 451-2635
[20]  
Iloeje U(2013)GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence Diabetes Obes Metab 15 15-1100